Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; pertactin; pertussis toxoid; tetanus toxoid; poliovirus; diphtheria toxoid -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; poliovirus; tetanus toxoid; pertactin; pertussis toxoid; hepatitis b surface antigen recombinant; polyribose ribitol phosphate - haemophilus influenzae type b; diphtheria toxoid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pertactin; diphtheria toxoid; pertussis toxoid; poliovirus; tetanus toxoid; pertussis filamentous haemagglutinin -

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, type 1 (mahoney) 40 d antigen, type 2 (mef-1) 8d antigen, type 3 (saukett) 32d antigen, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/0,5ml+ not less than 40iu/0,5ml+ 25mcg/0,5ml+ 25mcg/0,5ml+ 8mcg/0,5ml+ 10mcg /0,5ml+ units/0,5ml+ units/0,5ml+ units/0,5ml+ 10mcg /0,5ml

Ireland - English - HPRA (Health Products Regulatory Authority)

nuron biotech b.v. - neisseria meningitidis serogroup c (strain c11) polysaccharide, corynebacterium diphtheriae crm197 carrier protein, aluminium phosphate - solution for injection - 0.5 millilitre - meningococcal vaccines

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - rotavirus type g1, rotavirus type g2, rotavirus type g3, rotavirus type g4, rotavirus type p1a - solution oral - not less than 2,2x10^6iu+ not less than 2,8x106iu+ not less than 2,2x10^6iu+ not less than 2x10^6iu+ not less than 2,3x10^6iu

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - rotavirus type g1, rotavirus type g2, rotavirus type g3, rotavirus type g4, rotavirus type p1a - solution oral - not less than 2,2x10^6iu+ not less than 2,8x106iu+ not less than 2,2x10^6iu+ not less than 2x10^6iu+ not less than 2,3x10^6iu

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - corynebacterium diphtheriae crm197 carrier protein aluminium phosphate - solution for injection - 0.5 millilitre

Canada - English - Health Canada

glaxosmithkline inc - haemophilus influenzae type b-prp; filamentous haemagglutinin; pertactin; hepatitis b surface antigen (recombinant); diphtheria toxoid; tetanus toxoid; poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); pertussis toxoid; tetanus toxoid adsorbed - suspension - 10mcg; 25mcg; 8mcg; 10mcg; 25lf; 10lf; 40unit; 8unit; 32unit; 25mcg; 40mcg - haemophilus influenzae type b-prp 10mcg; filamentous haemagglutinin 25mcg; pertactin 8mcg; hepatitis b surface antigen (recombinant) 10mcg; diphtheria toxoid 25lf; tetanus toxoid 10lf; poliovirus type 1 mahoney (inactivated) 40unit; poliovirus type 2 mef1 (inactivated) 8unit; poliovirus type 3 saukett (inactivated) 32unit; pertussis toxoid 25mcg; tetanus toxoid adsorbed 40mcg - vaccines

United States - English - NLM (National Library of Medicine)

a-s medication solutions - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde in - infanrix is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the 7th birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of infanrix is a contraindication [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including in